Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...
In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...
1. In this retrospective observational cohort study of children in St. Louis, those with the highest risk of firearm injury ...
Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced meaningful improvements in alertness, behavior, and communication. In a randomized ...
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback